TGA Approval

ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial (330566)

ARTG ID

330566

ARTG Name

ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial

Sponsor

Alexion Pharmaceuticals Australasia Pty Ltd

ARTG Date

March 23, 2021

Registration Type

Medicine

Therapeutic Good Type

Medicine

Licence Status

Active

Licence Category

Registered

Sponsor Information

Sponsor Name

Sponsor Item Name

ALEXION PHARMACEUTICALS AUSTRALASIA PTY LTD

https://medical-cdn.nocode.com/drug_tga/03673dee6a630d3b5fe10624f5268b1e.pdf

https://medical-cdn.nocode.com/drug_tga/9f7ff1e1863095aa340de0da9ff657ec.pdf

Ingredient Name

ravulizumab

Empowering clinical research with data-driven insights and AI-powered tools.

ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial (330566) - TGA 批准文号 | MedPath